Filtered By:
Condition: Heart Attack
Therapy: Dialysis
This page shows you your search results in order of date. This is page number 3.
Order by Relevance | Date
Total 432 results found since Jan 2013.
Gender Difference of Blood Pressure Control Rate and Clinical Prognosis in Patients With Resistant Hypertension: Real-World Observation Study
CONCLUSION: In resistant hypertension, men were younger than women, but end-organ damage was more common and the risk of cardiovascular event was higher. More intensive cardiovascular prevention strategies may be required in male patients with resistant hypertension.PMID:37096308 | PMC:PMC10125792 | DOI:10.3346/jkms.2023.38.e124
Source: Journal of Korean Medical Science - April 25, 2023 Category: Biomedical Science Authors: Hyung Joon Joo Yunjin Yum Yong Hyun Kim Jung-Woo Son Sung Hea Kim Seonghoon Choi Seongwoo Han Mi-Seung Shin Jin-Ok Jeong Eung Ju Kim Working Group on Hypertension Complication Source Type: research
Minimally Invasive Mitral Valve Surgery in the Elderly
CONCLUSION: miMVS results in satisfactory early postoperative outcomes in elderly patients.PMID:36858067 | DOI:10.1055/s-0043-1762940
Source: The Thoracic and Cardiovascular Surgeon - March 1, 2023 Category: Cardiovascular & Thoracic Surgery Authors: Maximilian Franz Nunzio Davide De Manna Saskia Schulz Fabio Ius Axel Haverich Serghei Cebotari Igor Tudorache Jawad Salman Source Type: research
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Medicina (Kaunas). 2023 Feb 16;59(2):388. doi: 10.3390/medicina59020388.ABSTRACTSodium glucose cotransporter 2 inhibitor (SGLT2i) is a class of drugs that were originally intended for decreasing blood glucose in diabetes. However, recent trials have shown that there are other beneficial effects. Major clinical trials involving SGLT2i medications from 2015 to 2022 were reviewed using PUBMED search. Recent major SGLT2i landmark trials have demonstrated benefits for cardiovascular disease (reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death), hospitalization for heart failure, all-cause deat...
Source: Medicina (Kaunas) - February 25, 2023 Category: Universities & Medical Training Authors: Jonathan C H Chan Michael C Y Chan Source Type: research
